Review of etoposide single-agent activity
- 30 June 1982
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 9, 21-30
- https://doi.org/10.1016/s0305-7372(82)80074-1
Abstract
No abstract availableThis publication has 15 references indexed in Scilit:
- A phase II study of oral VP-16-213 in non-seminomatous testicular cancerEuropean Journal of Cancer (1965), 1981
- Randomisierte Phase-II-Studie mit VP-16–213 (Etoposide®) in der Behandlung vom fortgeschrittenen MammakarzinomOncology Research and Treatment, 1981
- VP16-213 as a single agent in advanced testicular tumorsEuropean Journal of Cancer (1965), 1980
- Etoposide (VP-16-213)Cancer Treatment Reviews, 1979
- Phase II evaluation of VP-16-213 (NSC-141540) in patients with advanced ovarian carcinoma resistant to alkylating agentsGynecologic Oncology, 1978
- Treatment of small cell anaplastic carcinoma of the lung with the oral solution of VP-16-213 (NSC 141540, 4′-demethylepipodophyllotoxin 9-(4,6-0-ethylidene-β-D-glucopyranoside)Cancer, 1977
- Evaluation of VP-16 and the Combination of Adriamycin and Vincristine in Advanced Breast CancerOncology, 1976
- Letter: Epipodophyllotoxin VP 16213 in acute non-lymphoblastic leukaemia.BMJ, 1975
- A clinical trial of the oral form of 4′-demethyl-epipodophyllotoxin-β-D ethylidene glucoside (NSC 141540) VP 16–213Cancer, 1975
- Epipodophyllotoxin VP 16213 in Treatment of Acute Leukaemia--Haematosarcoma and Solid TumoursBMJ, 1973